KALA
Price
$19.26
Change
+$2.36 (+13.96%)
Updated
Sep 24, 04:59 PM (EDT)
Capitalization
118.66M
SYRE
Price
$17.01
Change
+$0.99 (+6.18%)
Updated
Sep 24, 04:59 PM (EDT)
Capitalization
967.62M
43 days until earnings call
Interact to see
Advertisement

KALA vs SYRE

Header iconKALA vs SYRE Comparison
Open Charts KALA vs SYREBanner chart's image
Kala BIO
Price$19.26
Change+$2.36 (+13.96%)
Volume$1.33K
Capitalization118.66M
Spyre Therapeutics
Price$17.01
Change+$0.99 (+6.18%)
Volume$34.27K
Capitalization967.62M
KALA vs SYRE Comparison Chart in %
Loading...
KALA
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
SYRE
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
KALA vs. SYRE commentary
Sep 24, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is KALA is a Hold and SYRE is a StrongBuy.

Interact to see
Advertisement
COMPARISON
Comparison
Sep 24, 2025
Stock price -- (KALA: $16.90 vs. SYRE: $16.02)
Brand notoriety: KALA and SYRE are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: KALA: 91% vs. SYRE: 176%
Market capitalization -- KALA: $118.66M vs. SYRE: $967.62M
KALA [@Biotechnology] is valued at $118.66M. SYRE’s [@Biotechnology] market capitalization is $967.62M. The market cap for tickers in the [@Biotechnology] industry ranges from $97.36B to $0. The average market capitalization across the [@Biotechnology] industry is $1.91B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

KALA’s FA Score shows that 0 FA rating(s) are green whileSYRE’s FA Score has 0 green FA rating(s).

  • KALA’s FA Score: 0 green, 5 red.
  • SYRE’s FA Score: 0 green, 5 red.
According to our system of comparison, KALA is a better buy in the long-term than SYRE.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

KALA’s TA Score shows that 3 TA indicator(s) are bullish while SYRE’s TA Score has 4 bullish TA indicator(s).

  • KALA’s TA Score: 3 bullish, 5 bearish.
  • SYRE’s TA Score: 4 bullish, 6 bearish.
According to our system of comparison, both KALA and SYRE are a bad buy in the short-term.

Price Growth

KALA (@Biotechnology) experienced а -7.75% price change this week, while SYRE (@Biotechnology) price change was +8.10% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +4.31%. For the same industry, the average monthly price growth was +10.10%, and the average quarterly price growth was +53.89%.

Reported Earning Dates

SYRE is expected to report earnings on Nov 06, 2025.

Industries' Descriptions

@Biotechnology (+4.31% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
SYRE($968M) has a higher market cap than KALA($119M). KALA YTD gains are higher at: 143.516 vs. SYRE (-31.186). KALA has higher annual earnings (EBITDA): -31.92M vs. SYRE (-222.15M). SYRE has more cash in the bank: 527M vs. KALA (31.9M). SYRE has less debt than KALA: SYRE (0) vs KALA (29.9M). KALA (0) and SYRE (0) have equivalent revenues.
KALASYREKALA / SYRE
Capitalization119M968M12%
EBITDA-31.92M-222.15M14%
Gain YTD143.516-31.186-460%
P/E RatioN/A1.68-
Revenue00-
Total Cash31.9M527M6%
Total Debt29.9M0-
FUNDAMENTALS RATINGS
KALA vs SYRE: Fundamental Ratings
KALA
SYRE
OUTLOOK RATING
1..100
1079
VALUATION
overvalued / fair valued / undervalued
1..100
62
Fair valued
72
Overvalued
PROFIT vs RISK RATING
1..100
100100
SMR RATING
1..100
10098
PRICE GROWTH RATING
1..100
3485
P/E GROWTH RATING
1..100
9781
SEASONALITY SCORE
1..100
8521

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

KALA's Valuation (62) in the Pharmaceuticals Major industry is in the same range as SYRE (72). This means that KALA’s stock grew similarly to SYRE’s over the last 12 months.

KALA's Profit vs Risk Rating (100) in the Pharmaceuticals Major industry is in the same range as SYRE (100). This means that KALA’s stock grew similarly to SYRE’s over the last 12 months.

SYRE's SMR Rating (98) in the Pharmaceuticals Major industry is in the same range as KALA (100). This means that SYRE’s stock grew similarly to KALA’s over the last 12 months.

KALA's Price Growth Rating (34) in the Pharmaceuticals Major industry is somewhat better than the same rating for SYRE (85). This means that KALA’s stock grew somewhat faster than SYRE’s over the last 12 months.

SYRE's P/E Growth Rating (81) in the Pharmaceuticals Major industry is in the same range as KALA (97). This means that SYRE’s stock grew similarly to KALA’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
KALASYRE
RSI
ODDS (%)
Bearish Trend 2 days ago
90%
Bullish Trend 2 days ago
86%
Stochastic
ODDS (%)
Bearish Trend 2 days ago
90%
Bullish Trend 2 days ago
82%
Momentum
ODDS (%)
N/A
Bearish Trend 2 days ago
89%
MACD
ODDS (%)
Bearish Trend 2 days ago
90%
Bearish Trend 2 days ago
90%
TrendWeek
ODDS (%)
Bearish Trend 2 days ago
87%
Bullish Trend 2 days ago
83%
TrendMonth
ODDS (%)
Bullish Trend 2 days ago
79%
Bearish Trend 2 days ago
89%
Advances
ODDS (%)
Bullish Trend 6 days ago
78%
Bullish Trend 2 days ago
84%
Declines
ODDS (%)
Bearish Trend 2 days ago
88%
Bearish Trend 9 days ago
90%
BollingerBands
ODDS (%)
Bearish Trend 2 days ago
87%
Bullish Trend 2 days ago
78%
Aroon
ODDS (%)
Bullish Trend 2 days ago
79%
Bearish Trend 2 days ago
89%
View a ticker or compare two or three
Interact to see
Advertisement
KALA
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
SYRE
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
CRCRX9.740.08
+0.83%
NYLI CBRE Real Estate Class C
PNRCX48.300.29
+0.60%
PGIM Jennison Natural Resources C
NBPBX50.720.19
+0.38%
Neuberger Berman Large Cap Value Adv
FSCDX29.86N/A
N/A
Fidelity Advisor Small Cap A
LIGCX11.69-0.11
-0.93%
Loomis Sayles International Growth C

KALA and

Correlation & Price change

A.I.dvisor indicates that over the last year, KALA has been loosely correlated with ABCZF. These tickers have moved in lockstep 42% of the time. This A.I.-generated data suggests there is some statistical probability that if KALA jumps, then ABCZF could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To KALA
1D Price
Change %
KALA100%
-8.89%
ABCZF - KALA
42%
Loosely correlated
N/A
VICP - KALA
29%
Poorly correlated
N/A
ACIU - KALA
29%
Poorly correlated
-0.40%
SYRE - KALA
28%
Poorly correlated
+4.77%
VTGN - KALA
28%
Poorly correlated
+3.30%
More

SYRE and

Correlation & Price change

A.I.dvisor indicates that over the last year, SYRE has been loosely correlated with CGON. These tickers have moved in lockstep 59% of the time. This A.I.-generated data suggests there is some statistical probability that if SYRE jumps, then CGON could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To SYRE
1D Price
Change %
SYRE100%
+4.77%
CGON - SYRE
59%
Loosely correlated
-0.92%
IDYA - SYRE
59%
Loosely correlated
+0.04%
XNCR - SYRE
57%
Loosely correlated
-0.67%
CRNX - SYRE
56%
Loosely correlated
+6.35%
BEAM - SYRE
55%
Loosely correlated
-2.79%
More